NanOlogy Appoints David J. Arthur as Chief Executive Officer to Drive Clinical Development of its Large Surface Area Microparticle (LSAM) Investigational Drug Portfolio [Yahoo! Finance]
Salarius Pharmaceuticals, Inc. (SLRX)
Company Research
Source: Yahoo! Finance
This appointment reflects a pivotal step in NanOlogy's commitment to accelerating development of its LSAM drug portfolio including its development program targeting Diffuse Intrinsic Pontine Glioma (DIPG), a devastating pediatric brain cancer with limited treatment options. David brings over 35 years of pharmaceutical experience spanning product development, strategy, operations, and commercialization. Most recently, as CEO of Salarius Pharmaceuticals, Inc., David built Salarius into a multiproduct clinical stage oncology company and successfully took the company public with a listing on the NASDAQ exchange. Prior to his biotechnology CEO roles, David spent over 20 years in a variety of executive roles with Eli Lilly and Boehringer Ingelheim. "We believe David is a great addition to the team and will accelerate our existing drug development activities, business development plans, and new drug development programs. NanOlogy has completed clinical trials in 6 solid tumors with our
Show less
Read more
Impact Snapshot
Event Time:
SLRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SLRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SLRX alerts
High impacting Salarius Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
SLRX
News
- Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual MeetingGlobeNewswire
- Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate PlatformGlobeNewswire
- Salarius Pharmaceuticals (NASDAQ:SLRX) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Salarius Pharmaceuticals (NASDAQ:SLRX) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Salarius Pharmaceuticals (NASDAQ:SLRX) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
SLRX
Sec Filings
- 12/19/25 - Form DEFA14A
- 12/19/25 - Form 8-K
- 11/24/25 - Form 4
- SLRX's page on the SEC website